This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Cosciens Biopharma's Enterprise Value for the quarter that ended in Mar. 2026 was $0.28 Mil.
Cosciens Biopharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.73 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cosciens Biopharma EV-to-EBIT Related Terms
Cosciens Biopharma EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Cosciens Biopharma's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Cosciens Biopharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cosciens Biopharma EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cosciens Biopharma's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Cosciens Biopharma's EV-to-EBIT falls into.
Cosciens Biopharma's current Enterprise Value is $2.73 Mil.
Cosciens Biopharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.73 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cosciens Biopharma (CSCID) has a EV-to-EBIT of -0.41 as of Jul. 08, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Cosciens Biopharma and its competitors. According to the industry distribution chart, Cosciens Biopharma ranks #999999 out of 364 companies in the Biotechnology industry.
Is Cosciens Biopharma's EV-to-EBIT too high?
Cosciens Biopharma's current EV-to-EBIT is -0.41. Based on the distribution chart, Cosciens Biopharma ranks #999999 out of 364 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Cosciens Biopharma has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cosciens Biopharma's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cosciens Biopharma ranks #999999 out of 364 companies for EV-to-EBIT. This places Cosciens Biopharma in the lower half of its industry. The industry median EV-to-EBIT is 14.55. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 14.55, based on 364 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Cosciens Biopharma and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 14.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cosciens Biopharma's current EV-to-EBIT is -0.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosciens Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Cosciens Biopharma (CSCID) is currently considered Fairly Valued. The stock's GF Value™ is $6.57, compared to a current price of $7.00 — trading 6.5% above its estimated fair value. The current EV-to-EBIT is -0.41. Cosciens Biopharma's overall GF Score™ is 61/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Cosciens Biopharma (CSCID), the current EV-to-EBIT is -0.41 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cosciens Biopharma (CSCID) Overvalued in 2026?
Based on GuruFocus' analysis, Cosciens Biopharma stock appears to be overvalued.
The current stock price of $7.00 is trading 6.5% above its estimated GF Value™ of $6.57.
GuruFocus considers Cosciens Biopharma to be Fairly Valued.
Key valuation signals for CSCID:
EV-to-EBIT: -0.41
GF Value™: $6.57 vs. price of $7.00 (6.5% above fair value)
No single metric tells the full story. See the CSCID stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing pharmaceutical and diagnostic products and active ingredients for the healthcare and cosmetics industries. It operates through two segments: Active Ingredient and Biopharmaceutical. The Active Ingredient segment, which generates maximum revenue, focuses on plant-based ingredients derived from oats and other renewable resources, including oat beta glucan, oat oil, and avenanthramides. The Biopharmaceutical segment focuses on the development and commercialization of therapeutics and diagnostic tests, including its product Macrilen, and advancing a pre-clinical pipeline targeting unmet medical needs, particularly in rare or orphan indications. It operates in Canada, Germany, the United States, and Austria.
61GF Score
Get the complete analysis for CSCID
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSCID has been successfully added to your 
